Survival Curve from Scientific Research

Open access visualization of Survival Curve, RFS, Pembrolizumab Monotherapy, Sequential Therapy, Concurrent Therapy
CC-BY
1
Views
0
Likes

Citation

DOI: 10.1038/s41591-024-03077-5

DOI

RFS curve showing 12-month RFS rate was 89% with pembrolizumab monotherapy, 80% with sequential therapy and 84% with concurrent therapy; 24-month RFS rate was 66%, 80% and 75%, respectively.

#Survival Curve#RFS#Pembrolizumab Monotherapy#Sequential Therapy#Concurrent Therapy

Related Plots

Discover More Scientific Plots

Browse thousands of high-quality scientific visualizations from open-access research

Browse All PlotsView Collections